Trevi Therapeutics Inc (NASDAQ: TRVI) has experienced a decline in its stock price by -7.67 compared to its previous closing price of 3.00. However, the company has seen a fall of -3.15% in its stock price over the last five trading days. prnewswire.com reported 2024-11-06 that Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.
Is It Worth Investing in Trevi Therapeutics Inc (NASDAQ: TRVI) Right Now?
Additionally, the 36-month beta value for TRVI is 0.99. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TRVI is 43.76M and currently, short sellers hold a 3.92% ratio of that float. The average trading volume of TRVI on November 21, 2024 was 439.32K shares.
TRVI’s Market Performance
TRVI stock saw a decrease of -3.15% in the past week, with a monthly decline of -14.24% and a quarterly a decrease of 0.36%. The volatility ratio for the week is 8.22%, and the volatility levels for the last 30 days are 6.76% for Trevi Therapeutics Inc (TRVI). The simple moving average for the past 20 days is -7.05% for TRVI’s stock, with a -4.37% simple moving average for the past 200 days.
Analysts’ Opinion of TRVI
Many brokerage firms have already submitted their reports for TRVI stocks, with Leerink Partners repeating the rating for TRVI by listing it as a “Outperform.” The predicted price for TRVI in the upcoming period, according to Leerink Partners is $7 based on the research report published on September 09, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see TRVI reach a price target of $9. The rating they have provided for TRVI stocks is “Outperform” according to the report published on August 30th, 2024.
H.C. Wainwright gave a rating of “Buy” to TRVI, setting the target price at $6 in the report published on August 30th of the current year.
TRVI Trading at -11.16% from the 50-Day Moving Average
After a stumble in the market that brought TRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.75% of loss for the given period.
Volatility was left at 6.76%, however, over the last 30 days, the volatility rate increased by 8.22%, as shares sank -13.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.06% lower at present.
During the last 5 trading sessions, TRVI fell by -3.15%, which changed the moving average for the period of 200-days by +89.73% in comparison to the 20-day moving average, which settled at $2.98. In addition, Trevi Therapeutics Inc saw 106.72% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRVI starting from GOOD JENNIFER L, who sale 4,219 shares at the price of $3.03 back on Sep 06 ’24. After this action, GOOD JENNIFER L now owns 213,313 shares of Trevi Therapeutics Inc, valued at $12,784 using the latest closing price.
GOOD JENNIFER L, the President & CEO of Trevi Therapeutics Inc, sale 1,840 shares at $3.04 during a trade that took place back on Sep 09 ’24, which means that GOOD JENNIFER L is holding 213,313 shares at $5,587 based on the most recent closing price.
Stock Fundamentals for TRVI
Current profitability levels for the company are sitting at:
- -273.95 for the present operating margin
- 0.39 for the gross margin
The net margin for Trevi Therapeutics Inc stands at -251.8. The total capital return value is set at -0.81. Equity return is now at value -59.65, with -53.78 for asset returns.
Currently, EBITDA for the company is -33.8 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 1124.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.38.
Conclusion
In conclusion, Trevi Therapeutics Inc (TRVI) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
